A Review of CD4+ T Cell-mediated Immune Drift and Mechanisms in the Treatment of Immune Inflammatory Skin Diseases with Biological Agents

Fangyuan Miao , Chen Luo , Jinfeng Chen , Changjie Shang , Zechao Zhang , Liuyun Yang , Min Zhu

›› 2025, Vol. 4 ›› Issue (2) : 128 -134.

PDF
›› 2025, Vol. 4 ›› Issue (2) : 128 -134. DOI: 10.14218/FIM.2024.00057
Review Articles
research-article

A Review of CD4+ T Cell-mediated Immune Drift and Mechanisms in the Treatment of Immune Inflammatory Skin Diseases with Biological Agents

Author information +
History +
PDF

Abstract

Immunoinflammatory skin diseases are characterized by an imbalance in immune homeostasis, and their chronic inflammatory processes involve a complex regulatory network of CD4+ T cell differentiation. With the widespread use of biologics (e.g., interleukin-17/interleukin-23 inhibitors) in psoriasis, atopic dermatitis, and other diseases, the adverse effects triggered by the phenomenon of CD4+ T cell-mediated immune drift have attracted significant attention, with the skin being the primary target as an immune organ. In this paper, we provide a review of the clinical features of the skin and the mechanisms of immune drift caused by different types of biologics, as well as the therapeutic modalities.

Keywords

Adverse reactions / Biological agents / Immune drift / Skin / CD4+ T cells / IL-17 inhibitors / IL-12/23 inhibitors / IL-4/13 inhibitors / PD-1/PD-L1 inhibitors / TNF-α inhibitors

Cite this article

Download citation ▾
Fangyuan Miao, Chen Luo, Jinfeng Chen, Changjie Shang, Zechao Zhang, Liuyun Yang, Min Zhu. A Review of CD4+ T Cell-mediated Immune Drift and Mechanisms in the Treatment of Immune Inflammatory Skin Diseases with Biological Agents. , 2025, 4(2): 128-134 DOI:10.14218/FIM.2024.00057

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome 2018; 6(1):221. doi:10.1186/s40168-018-0603-4, PMID:30545401.

[2]

Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, et al. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. Biologics 2021; 15:1-15. doi:10.2147/BTT.S285610, PMID:33442230.

[3]

Cunliffe A, Gran S, Ali U, Grindlay D, Lax SJ, Williams HC, et al. Can atopic eczema and psoriasis coexist? A systematic review and metaanalysis. Skin Health Dis 2021; 1(2):e29. doi:10.1002/ski2.29, PMID: 35664974.

[4]

de Felici Del Giudice MB, Ravaglia G, Brusasco M, Satolli F. Managing the Overlap: Therapeutic Approaches in Patients with Concomitant Psoriasis and Atopic Dermatitis-A Case Series. J Clin Med 2025; 14(3):796. doi:10.3390/jcm14030796, PMID:39941467.

[5]

Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, et al. Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology 2011; 223(1):57-67. doi:10.1159/000330330, PMID:21865674.

[6]

Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 2015; 74(1):5-17. doi:10.1016/j.cyto.2014.09.011, PMID:25458968.

[7]

Barberis M, Rojas López A. T cell phenotype switching in autoimmune disorders: Clinical significance of targeting metabolism. Clin Transl Med 2022; 12(7):e898. doi:10.1002/ctm2.898, PMID:35904141.

[8]

An R, Deng YH. Advances in Cutaneous Side Effects and Treatment of Tumor Necrosis Factor Alpha Inhibitors. Chin J Dermatolvenereol 2020; 34(9):1078-1082. doi:10.13735/j.cjdv.1001-7089.201911046.

[9]

Menegatti S, Bianchi E, Rogge L. Anti-TNF Therapy in Spondyloar thritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses. Front Immunol 2019;10:382. doi:10.3389/fimmu.2019.00382, PMID:30941119.

[10]

Segaert S, Hermans C. Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents. Am J Clin Dermatol 2017; 18(6):771-787. doi:10.1007/ s40257-017-0296-7, PMID:28597181.

[11]

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2020; 34(7):1440-1448. doi:10.1111/jdv.16246, PMID:31997406.

[12]

Pagan-Leon S, Werbel T, Montanez-Wiscovich M. Tumor Necrosis Factor Inhibitor-Induced Eczematous Eruption: A Report of Two Cases and Review of the Literature. Cureus 2021; 13(5):e15078. doi:10.7759/cureus.15078, PMID:34159000.

[13]

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med 2016; 164(1):10-22. doi:10.7326/M15-0729, PMID:26641955.

[14]

Magalhães CMC, Bartholo MR, Correa BHM, Ferrari MLA, Ferrari TCA. Dermatoses in patients with inflammatory bowel disease under tumor necrosis factor-alpha inhibitors treatment. Med Clin (Barc) 2025; 164(4):173-177. doi:10.1016/j.medcli.2024.09.004, PMID:395 16105.

[15]

Zhu E, Zhang S, Zhang X. Pathogenesis of Th2-type lmmune Phenotypic Switching Induced by Biologics for Plaque Psoriasis. Chin J Dermatolvenereol 2023; 37(10):1099-1102. doi:10.13735/j.cjdv.1001-7089.202303087.

[16]

Stoffel E, Maier H, Riedl E, Brüggen MC, Reininger B, Schaschinger M, et al. Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics. Br J Dermatol 2018; 178(5):1151-1162. doi:10.1111/ bjd.16126, PMID:29143979.

[17]

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014; 371(4):326-338. doi:10.1056/NEJMoa1314258, PMID:25007392.

[18]

Yang X, Zhou J, Dong Y, Zhao Z. Literature analysis of adverse drug reactions induced by IL-17A inhibitors: secukinumab and ixekizumab. Chin J New Drugs 2022; 31(10):1027-1032.

[19]

Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D’Adamio S, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther 2020; 20(6):665-672. doi:10.1080/14712598.2020.1727439, PMID:32045273.

[20]

Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol 2019; 181(3):604-606. doi:10.1111/bjd.17779, PMID:30768788.

[21]

Yatsuzuka K, Muto J, Shiraishi K, Fujisawa Y, Murakami M. Paradoxical eczema associated with interleukin-17A inhibitor use in a patient with generalized pustular psoriasis accompanied by asthma. Cureus 2024; 16(7):e64680. doi:10.7759/cureus.64680.

[22]

Mi W, Li M, Li F, Xiao Y, Wang J, Khalik BNA, et al. Secukinumabinduced Eezema-like Dermatitis in Patients with Plaque Psoriasis Successfully Treated with Ustekinumab: Two Cases Report. Chin J Dermatolvenereol 2024; 38(5):522-525. doi:10.13735/j.cjdv.1001-7089.202307050.

[23]

He J, Wang R, Zhang X, Li C. Local Eczema-Like Dermatitis Caused by Secukinumab in the Treatment of Nail Psoriasis: A Case Report. Chin J Dermatolvenereol 2024; 38(6):644-647. doi:10.13735/j.cjdv.1001-7089.202305106.

[24]

Potestio L, Ruggiero A, Martora F, Megna M. Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study. Arch Dermatol Res 2024; 317(1):102. doi:10.1007/s00403-024- 03594-w, PMID:39666087.

[25]

Napolitano M, Gallo L, Patruno C, Fabbrocini G, Megna M. Eczematous reaction to ixekizumab successfully treated with dupilumab. Dermatol Ther 2020; 33(2):e13218. doi:10.1111/dth.13218, PMID: 31912951.

[26]

Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin- 17A: does interleukin-22 play a key role? Clin Exp Dermatol 2022; 47(5):918-925. doi:10.1111/ced.15052, PMID:34862807.

[27]

Paolino G, Di Nicola MR, Brianti P, Bianchi VG, Mercuri SR. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: The role of systemic treatments as a possible trigger. Dermatol Ther 2022; 35(11):e15814. doi:10.1111/dth.15814, PMID:36088634.

[28]

Dainichi T, Kitoh A, Otsuka A, Nakajima S, Nomura T, Kaplan DH, et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat Immunol 2018; 19(12):1286-1298. doi:10.1038/ s41590-018-0256-2, PMID:30446754.

[29]

Guttman-Yassky E, Krueger JG. IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. J Invest Dermatol 2018; 138(7):1467-1469. doi:10.1016/j.jid.2018.02.037, PMID:29941097.

[30]

Chang J, Qi M, Wang Y, Li Y, Shi T. Bullous pemphigoid occurred in a patient with severe plaque psoriasis treated with secukinumab: a case report. China J Lepr Skin Dis 2024; 40(3):199-201. doi:10.12144/ zgmfskin202403199.

[31]

Cui Y, Yang Q, Wu W, Liu Y, Sun Y. Bullous Pemphigoid in a Psoriasis Patient After Secukinumab Treatment: A Case Report. Dermatology Bulletin 2024;41(2):209-213.

[32]

Ishiuji Y, Umezawa Y, Asahina A, Fukuta H, Aizawa N, Yanaba K, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases. J Dermatol 2018; 45(6):732-734. doi:10.1111/1346- 8138.14295, PMID:29569296.

[33]

Shi W, Zhao Z, Zhai Y, Ye X, Xu F. Adverse events associated with IL- 23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis. BMC Pharmacol Toxicol 2025; 26(1):11. doi:10.1186/s40360-025-00837-y, PMID:39833957.

[34]

Pernet C, Guillot B, Bessis D. Eczematous drug eruption after ustekinumab treatment. Arch Dermatol 2012; 148(8):959-960. doi:10.1001/archdermatol.2012.586, PMID:22911203.

[35]

Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy 2020; 50(1):5-14. doi:10.1111/cea.13491, PMID:31505066.

[36]

Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep 2018; 4(7):708-710. doi:10.1016/j.jdcr.2018.05.014, PMID:30128344.

[37]

Mirza FN, Wang A, Ramachandran SM, Damsky W, Cohen JM. Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report. Br J Dermatol 2021; 185(2):432-434. doi:10.1111/bjd.20064, PMID:33730377.

[38]

Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol 2019; 44(3):e49-e50. doi:10.1111/ced.13901, PMID:30656722.

[39]

Cirone KD, Lovegrove FE. Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report. SAGE Open Med Case Rep 2025;13:2050313X251317811. do i:10.1177/2050313X251317811, PMID:39906475.

[40]

Matsuda T, Yamada H, Hida N, Nakaizumi T, Yamada E, Satoh H, et al. An asthmatic case of psoriasiform eruption caused by administration of dupilumab. Allergol Int 2020; 69(3):478-479. doi:10.1016/j.alit.2020.02.004, PMID:32178985.

[41]

Yang Z, Pan M, Zhao X. Dupilumab-induced immune drifting from atopic dermatitis to polymyalgia rheumatica: a case report. China J Lepr Skin Dis 2023; 39(7):508-511. doi:10.12144/zgmfskin202307508.

[42]

Chen Y, Ni J, Li M, Hong Y, Zhu K, Hong R, et al. Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study. Front Pediatr 2024;12:1524962. doi:10.3389/ fped.2024.1524962, PMID:39895989.

[43]

Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31(5):e254-e257. doi:10.1111/jdv.14011, PMID:27739129.

[44]

Eshaq AM, Flanagan TW, Ba Abbad AA, Makarem ZAA, Bokir MS, Alasheq AK, et al. Immune Checkpoint Inhibitor-Associated Cu taneous Adverse Events: Mechanisms of Occurrence. Int J Mol Sci 2024; 26(1):88. doi:10.3390/ijms26010088, PMID:39795946.

[45]

Zhou Y, Xu F, Chen XY, Yan BX, Wang ZY, Chen SQ, et al. The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry. Cell Mol Immunol 2022; 19(12):1400-1413. doi:10.1038/s41423-022-00940-8, PMID:36348078.

[46]

Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Am J Clin Dermatol 2018; 19(3):345-361. doi:10.1007/s40257-017-0336-3, PMID:29256 113.

[47]

Saggau C, Bacher P, Esser D, Rasa M, Meise S, Mohr N, et al. Autoantigen- specific CD4(+) T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity 2024; 57(10):2416-2432.e8. doi:10.1016/j.immuni.2024.08.005, PMID:39226901.

[48]

Yosef N, Shalek AK, Gaublomme JT, Jin H, Lee Y, Awasthi A, et al. Dynamic regulatory network controlling TH 17 cell differentiation. Nature 2013; 496(7446):461-468. doi:10.1038/nature11981, PMID:23467089.

[49]

Napolitano M, Scalvenzi M, Fabbrocini G, Cinelli E, Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series. Dermatol Ther 2019; 32(6):e13142. doi:10.1111/dth.13142, PMID:31664761.

[50]

Lee J, Choi HK, Shin HS, Kim GD. Natural Products as Modulators of Aryl Hydrocarbon Receptor Signaling in Atopic Dermatitis Management. Molecules 2024; 29(24):5951. doi:10.3390/molecules29245951, PMID:39770040.

[51]

Anitua E, Tierno R, Martínez de Lagrán Z, Alkhraisat MH. Bioactive Effect of Plasma-Rich in Growth Factors (PRGFs) on Cell-Based In Vitro Models of Skin Inflammation in Relation to Inflammatory Skin Disorders. Cureus 2024; 16(11):e74252. doi:10.7759/cureus.74252, PMID:39712761.

[52]

Lynch RI, Lavelle EC. Immuno-modulatory biomaterials as antiinflammatory therapeutics. Biochem Pharmacol 2022;197:114890. doi:10.1016/j.bcp.2021.114890, PMID:34990595.

[53]

Vafaei-Nodeh S, Kabiri-Abyaneh S. Long-term control of atopic dermatitis with platelet-rich plasma. JAAD Case Rep 2021; 7:54-56. doi:10.1016/j.jdcr.2020.10.036, PMID:33319006.

[54]

Bunjaj A, Brandao L, Siracuse K, Soti V. Platelet-Rich Plasma for the Treatment of Plaque Psoriasis: A Systematic Review. Cureus 2023; 15(12):e50356. doi:10.7759/cureus.50356, PMID:38089952.

[55]

Lee YI, Lee SG, Kim J, Choi S, Jung I, Lee JH. Proteoglycan Combined with Hyaluronic Acid and Hydrolyzed Collagen Restores the Skin Barrier in Mild Atopic Dermatitis and Dry, Eczema-Prone Skin: A Pilot Study. Int J Mol Sci 2021; 22(19):10189. doi:10.3390/ijms221910189, PMID:34638528.

[56]

Slavkova M, Lazov C, Spassova I, Kovacheva D, Tibi IP, Stefanova D, et al. Formulation of Budesonide-Loaded Polymeric Nanoparticles into Hydrogels for Local Therapy of Atopic Dermatitis. Gels 2024; 10(1):79. doi:10.3390/gels10010079, PMID:38275852.

AI Summary AI Mindmap
PDF

506

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/